leisure time -WSS

leisure time

author：focus 2025-09-30 21:58:05 - browse：92

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Petition to FDA: Get the lead out of consumer hair dyes

WSS

Mayo Clinic plans $5B tech

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

With clinical trial data readouts, here's how to spot spin

Rep. Raul Ruiz on the physician shortage and more

FDA investigates CAR

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Trump demands the U.S. pay no more for drugs than other countries … again

What to know about OceanGate, the company behind the missing Titanic submersible

Medical leaders decry Supreme Court decision on affirmative action

Palantir health business leans on meeting customers’ needs

Apple is now the first public company to be valued at $3 trillion

J&J to emphasize cancer drugs, stop much of its vaccine research

Peter Hotez and the public health issue of online harassment

Retired US general questions alleged Putin, Prigozhin meeting

The high cost of giving birth even with insurance

CDC director unscathed in first congressional testimony

hotspot

Bulgari apologizes to China for listing Taiwan as a country after online backlash

With clinical trial data readouts, here's how to spot spin

Despite FDA concern, risk that CAR

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Takeda, Janssen join wearable maker to measure scratching

Diagnostic tests are hitting their mathematical limits

Wikipedia

explore

hotspot

hotspot